Results 161 to 170 of about 32,827 (233)

Landscape of splicing factors in early-onset gastric cancer reveals SRSF1 as a key driver of oxaliplatin resistance. [PDF]

J Biol Chem
Zhong B, Xiong Z, Xu H, Zheng J, Mohamed SA, Sun J, Huang D, Deng Z, Guo J, Peng J, Chen Y, Lian L.   +11 more
europepmc   +1 more source

OCT2 demethylation cracks open oxaliplatin resistance [PDF]

Nature Reviews Nephrology, 2016
openaire   +1 more source

Endothelin-1 Mediates Oxaliplatin Resistance via Activation of YAP Signaling in Colorectal Cancer. [PDF]

Oncol Res
Yang R, Yuan D, Liang C, Zhu S, Huang J, Zhang Y, He W, Li Q, Zhang H.   +8 more
europepmc   +1 more source

Fusobacterium nucleatum enhances oxaliplatin resistance in colon cancer by increasing PVT1 expression. [PDF]

J Transl Med
Gao K, Zhang J, Liu C, Yang Y, Wang J, Zhang J, Ma H, Wang F, Zhao L, Wang G.   +9 more
europepmc   +1 more source

Multidrug resistance-associated protein 2 (MRP2) and oxaliplatin transport

, 2015
The platinum-based drug oxaliplatin is currently used in the clinical treatment of gastrointestinal cancer. Efflux membrane transporters have been reported to play roles in determining the cellular accumulation and activity of platinum-based drugs, but ...
Myint, Khine
core  

Exportin 1 inhibitor KPT‑330 reverses oxaliplatin resistance via p53 nuclear retention in colorectal cancer. [PDF]

Int J Mol Med
Lai C, Jia X, Chen Y, Chen K, Wang F, Zhang Q, Xiang X, Chen ZS, Xu L, Dai S.   +9 more
europepmc   +1 more source

Targeting the ARL4C/RAP1/PI3K-Akt-mTOR signaling loop promotes ARL4C ubiquitination and reverses oxaliplatin resistance in colorectal cancer. [PDF]

Theranostics
Wang Y, Chang Z, Sun Z, Wang L, Li J, Li G, Wang Y, Zhang J, Ai L, Zhang Z, Dong J, Liu M.   +11 more
europepmc   +1 more source

Network Pharmacology and Experimental Validation to Explore the Potential Mechanism of Salvianolic Acid B in Reversing Oxaliplatin Resistance of Colorectal Cancer Cells. [PDF]

IET Syst Biol
Liang W, Li B, Yang H, Sun Y, Yang H, Hu X, Huang R, Hu T, Wu C, He X, Sun Y.   +10 more
europepmc   +1 more source

ΔNp73 overexpression induces oxaliplatin-resistance in colon cancer

, 2015
Peer ...
Bonilla, Félix, Domínguez, Gemma
openaire   +1 more source

Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer

BACKGROUND: A major problem in cancer chemotherapy is the existence of primary resistance and/or the acquisition of secondary resistance. Many cellular defects contribute to chemoresistance, but epigenetic changes can also be a cause.
Navarro-Pérez, Valentin, Élez, Elena, Cassingena, Andrea, Martínez-Balibrea, Eva, Tabernero Caturla, Josep, Carmona, F. Javier, Siena, Salvatore, Esteller, Manel, Musulen, Eva, Martínez Cardús, Anna, Sartore-Bianchi, Andrea, Abad, Albert, Moutinho, Cátia, Santos, Cristina, Salazar Soler, Ramón   +14 more
core